Vasundhara Rasayans Ltd
Incorporated in 1987, Vasundhara Rasayans Ltd is a manufacturer and exporter of Antacids[1]
- Market Cap ₹ 50.0 Cr.
- Current Price ₹ 157
- High / Low ₹ 221 / 100
- Stock P/E 13.2
- Book Value ₹ 123
- Dividend Yield 1.27 %
- ROCE 16.6 %
- ROE 12.6 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 61.2 to 44.6 days.
Cons
- The company has delivered a poor sales growth of 9.93% over past five years.
- Earnings include an other income of Rs.3.04 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.83 | 18.40 | 15.27 | 15.41 | 16.58 | 19.71 | 21.17 | 22.68 | 26.70 | 37.88 | 36.96 | 33.99 | 31.59 | |
| 17.27 | 16.80 | 13.97 | 13.76 | 14.78 | 18.55 | 18.33 | 19.57 | 24.49 | 32.32 | 30.53 | 29.88 | 28.62 | |
| Operating Profit | 3.56 | 1.60 | 1.30 | 1.65 | 1.80 | 1.16 | 2.84 | 3.11 | 2.21 | 5.56 | 6.43 | 4.11 | 2.97 |
| OPM % | 17.09% | 8.70% | 8.51% | 10.71% | 10.86% | 5.89% | 13.42% | 13.71% | 8.28% | 14.68% | 17.40% | 12.09% | 9.40% |
| 0.14 | 0.31 | 0.25 | 0.44 | 7.74 | 1.04 | 1.15 | 0.99 | 1.04 | 2.30 | 1.94 | 2.35 | 3.04 | |
| Interest | 0.64 | 0.53 | 0.57 | 0.39 | 0.17 | 0.08 | 0.06 | 0.09 | 0.09 | 0.25 | 0.21 | 0.34 | 0.41 |
| Depreciation | 0.92 | 0.50 | 0.56 | 0.56 | 0.32 | 0.05 | 0.03 | 0.05 | 0.12 | 0.13 | 0.26 | 0.36 | 0.42 |
| Profit before tax | 2.14 | 0.88 | 0.42 | 1.14 | 9.05 | 2.07 | 3.90 | 3.96 | 3.04 | 7.48 | 7.90 | 5.76 | 5.18 |
| Tax % | 34.11% | 34.09% | 45.24% | 59.65% | 28.07% | 29.95% | 23.59% | 25.76% | 28.62% | 25.27% | 25.82% | 26.39% | |
| 1.41 | 0.58 | 0.24 | 0.46 | 6.52 | 1.45 | 2.99 | 2.94 | 2.17 | 5.59 | 5.86 | 4.25 | 3.80 | |
| EPS in Rs | 4.44 | 1.82 | 0.76 | 1.45 | 20.51 | 4.56 | 9.41 | 9.25 | 6.83 | 17.59 | 18.44 | 13.37 | 11.96 |
| Dividend Payout % | 11.28% | 27.41% | 0.00% | 69.13% | 4.88% | 21.93% | 15.95% | 16.22% | 14.65% | 0.00% | 0.00% | 14.96% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 10% |
| 3 Years: | 8% |
| TTM: | -15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 8% |
| 3 Years: | 31% |
| TTM: | -36% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 4% |
| 3 Years: | 1% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 16% |
| 3 Years: | 18% |
| Last Year: | 13% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 |
| Reserves | 3.33 | 3.72 | 3.96 | 4.04 | 10.56 | 11.63 | 14.23 | 16.69 | 18.36 | 23.64 | 28.76 | 32.38 | 35.93 |
| 4.44 | 5.58 | 5.01 | 3.10 | 1.41 | 0.46 | 0.00 | 0.00 | 1.31 | 4.02 | 1.95 | 4.21 | 5.34 | |
| 3.47 | 4.16 | 3.21 | 3.13 | 5.23 | 5.56 | 7.28 | 3.14 | 2.66 | 3.68 | 3.41 | 3.30 | 3.70 | |
| Total Liabilities | 14.42 | 16.64 | 15.36 | 13.45 | 20.38 | 20.83 | 24.69 | 23.01 | 25.51 | 34.52 | 37.30 | 43.07 | 48.15 |
| 5.79 | 7.62 | 7.28 | 6.78 | 0.10 | 0.20 | 0.30 | 0.67 | 0.91 | 0.86 | 2.43 | 2.49 | 2.54 | |
| CWIP | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.18 | 0.23 | 0.18 | 0.07 | 1.10 | 1.23 | 0.97 | 1.12 | 0.32 | 0.00 | 1.16 | 2.35 | 4.28 |
| 8.14 | 8.79 | 7.90 | 6.60 | 19.18 | 19.40 | 23.42 | 21.22 | 24.28 | 33.66 | 33.71 | 38.23 | 41.33 | |
| Total Assets | 14.42 | 16.64 | 15.36 | 13.45 | 20.38 | 20.83 | 24.69 | 23.01 | 25.51 | 34.52 | 37.30 | 43.07 | 48.15 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.18 | 1.56 | 1.32 | 2.42 | -10.70 | 0.43 | 0.36 | 0.22 | 7.90 | -6.50 | 6.03 | -5.83 | |
| -0.51 | -2.02 | -0.06 | 0.07 | 13.30 | 0.53 | 1.02 | 0.16 | 1.39 | 1.27 | -1.32 | 0.46 | |
| -2.88 | 0.46 | -1.28 | -2.24 | -2.26 | -1.36 | -0.87 | -0.49 | 0.79 | 2.19 | -2.88 | 1.35 | |
| Net Cash Flow | -0.21 | 0.00 | -0.01 | 0.24 | 0.33 | -0.41 | 0.50 | -0.12 | 10.08 | -3.04 | 1.83 | -4.02 |
| Free Cash Flow | 2.69 | -0.50 | 1.10 | 2.38 | 3.34 | 0.29 | 0.23 | -0.20 | 7.55 | -6.58 | 4.20 | -6.25 |
| CFO/OP | 110% | 117% | 114% | 164% | -457% | 153% | 36% | 51% | 397% | -95% | 125% | -78% |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65.71 | 74.39 | 93.22 | 89.53 | 131.65 | 94.63 | 107.41 | 99.30 | 100.34 | 77.57 | 61.43 | 44.56 |
| Inventory Days | 39.14 | 45.71 | 53.90 | 69.11 | 64.32 | 60.51 | 59.00 | 48.01 | 57.91 | 79.48 | 38.86 | 44.33 |
| Days Payable | 42.15 | 59.78 | 31.68 | 52.91 | 62.28 | 45.28 | 59.39 | 76.61 | 57.65 | 48.68 | 40.43 | 42.91 |
| Cash Conversion Cycle | 62.70 | 60.32 | 115.44 | 105.73 | 133.69 | 109.85 | 107.02 | 70.70 | 100.60 | 108.36 | 59.85 | 45.98 |
| Working Capital Days | 31.54 | 11.90 | 12.43 | 14.69 | 258.67 | 245.56 | 267.41 | 143.88 | 127.82 | 174.50 | 193.76 | 274.47 |
| ROCE % | 24.41% | 12.04% | 8.04% | 13.44% | 14.21% | 14.14% | 23.75% | 21.73% | 12.92% | 28.79% | 25.06% | 16.56% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Domestic Sales INR Lakhs |
|
||||||||||
| Export Sales INR Lakhs |
|||||||||||
| Number of Permanent Employees Number |
|||||||||||
| Debtors Turnover Ratio Times |
|||||||||||
| Annual Production Capacity (Powder or equivalent) MT |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual Secretarial Compliance Report for year ended 31 March 2026 shows nil non-compliance.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 May - Newspaper Advertisement pertaining Audited financial results for the quarter and year ended on 31.03.2026
-
Announcement under Regulation 30 (LODR)-Change in Management
28 May - Ravi Jain appointed Additional Non-Executive Independent Director for five years from 28 May 2026.
-
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
28 May - Board approved MoU-cum loan-lease with holding company for API manufacturing at Dahej facility.
-
Intimation Under Reg 30 SEBI(LODR), 2015 Regarding Reconstitution Of Committees
28 May - Board reconstituted Audit, NRC and SRC committees effective 29 May 2026 after Pradeep Kumar Jain’s retirement.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
VRL manufactures and exports Antacids
therapeutic category of Active Pharma Ingredients and offers products in paste, powder and micronized grade of powder. Additionally, it offers products which are used other than pharmaceutical use.